1) Higashihara E, Nutahara K, Kojima M. et at : Prevalence and renal prognosis of diagnosed autosomal dominant polycystic kidney disease in Japan. Nephron 80: 421-427, 1998
2) Hildebrandt F, Benzing T: and Katsanis N : Ciliapathies. N Engi J Med 364: 1533-1543, 2011
3) Torres VE, Boletta A, Chapman A, et al : Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. J Am Soc Nephrol 5 : 1312-1329, 2010
4) Hogan MC, Masyuk TV, Page LJ, et al : Randomized clinical trial of long- acting somatostatin for autosomal dominant polycystic kidney and liver disease.J Am Soc Nephrol 21: 1052-1061, 2010
5) Higashihara E, Torres VE, Chapman AB, et al : Tolvaptan in utosomal dominant polycystic kidney disease : Three years experience. Clin J Am Soc Nephrol 6: 2499-2507, 2011